IART Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
411.2M
-1.8%
418.8M
+6.8%
391.9M
-9.9%
434.9M
+8.2%
402.1M
Cost of Revenue
201.3M
+1.2%
199.0M
+13.8%
174.9M
-18.3%
214.1M
+9.7%
195.1M
Gross Profit
209.9M
-4.5%
219.7M
+1.3%
217.0M
-1.8%
220.9M
+6.7%
207.0M
Operating Expenses
191.0M
-4.7%
200.5M
-2.5%
205.5M
+3.9%
197.8M
+1.3%
195.2M
R&D
21.9M
-9.7%
24.3M
+3.2%
23.5M
-5.2%
24.8M
+10.4%
22.5M
SG&A
165.3M
-4.1%
172.4M
-3.3%
178.2M
+5.3%
169.3M
+0.1%
169.0M
Operating Income
18.9M
-2.0%
19.3M
+68.1%
11.5M
-50.2%
23.0M
+95.9%
11.8M
EBITDA
58.0M
+0.9%
57.4M
+15.1%
49.9M
-18.8%
61.5M
+22.2%
50.3M
Net Income
14.9M
+231.4%
4.5M
+197.1%
-4617000
-171.0%
-1704000
+68.5%
-5404000
EPS (Basic)
$0.19
+216.7%
$0.06
+200.0%
$-0.06
-200.0%
$-0.02
+71.4%
$-0.07
EPS (Diluted)
$0.19
+216.7%
$0.06
+200.0%
$-0.06
-200.0%
$-0.02
+71.4%
$-0.07
Shares (Diluted)
78.6M
+0.5%
78.2M
+1.6%
77.0M
+0.2%
76.8M
+0.0%
76.8M
Integra LifeSciences (IART) โ€” Financials